EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Direct or Indirect Action? Mechanisms of the Antiatherosclerotic Effects of Glucagon‐Like Peptide‐1 Receptor Agonists

Michał Zawadzki iD, Monika Karczewska-Kupczewska

Cardiovascular Therapeutics · 2026

DOI: 10.1155/cdr/8388511 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cardiovascular Therapeutics, 2026. Verfasst von Michał Zawadzki und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Metabolic Diseases, Medical University of Białystok, Białystok, Poland, umb.edu.pl. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Atherosclerosis, Incretins, Anti-Inflammatory Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 137 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cardiovascular diseases (CVD) remain the leading cause of global mortality. Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) significantly reduce major adverse cardiovascular events in patients with and without Type 2 diabetes, offering benefits that extend beyond glycemic control. This review summarizes proposed multifactorial mechanisms underlying these effects, categorizing them into indirect and direct pathways. Indirect mechanisms include, among others, improvements in lipid metabolism, insulin sensitivity, blood pressure, and renal protection. In addition to the previously described effects, GLP‐1 RAs may exert direct vascular actions, including anti‐inflammatory actions, suppression of oxidative stress, improved endothelial function, modulation of macrophage polarization, reduction of adhesion molecule expression, and inhibition of vascular smooth muscle cell proliferation and migration, as well as downregulation of matrix metalloproteinases and plasminogen activator inhibitor‐1. Collectively, these processes contribute to plaque stabilization and reduced atherothrombotic risk. Although clinical evidence for cardiovascular risk reduction of GLP‐1 RAs is robust, mechanistic insights are predominantly derived from preclinical or animal models. Therefore, further functional studies in humans are warranted to clarify the direct antiatherogenic actions of GLP‐1 RAs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsAtherosclerosisIncretinsAnti-Inflammatory AgentsHumansAnimalsGlucagon-Like Peptide-1 ReceptorSignal TransductionPlaque, AtheroscleroticTreatment OutcomeInflammation Mediators

Stichwörter der Autor:innen

GLP-1 receptor agonistsatherosclerosiscardiovascular diseaseendothelial dysfunctioninflammation

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide-1 ReceptorIncretinsGLP1R protein, humanAnti-Inflammatory AgentsInflammation Mediators

Autor:innen und Institutionen

  • Department of Internal Medicine and Metabolic Diseases, Medical University of Białystok, Białystok, Poland, umb.edu.pl.
  • Department of Metabolic Diseases, Medical University of Białystok, Białystok, Poland, umb.edu.pl.

ORCID-Profile: Michał Zawadzki

Zitieren

APA

Zawadzki, M., & Karczewska-Kupczewska, M. (2026). Direct or Indirect Action? Mechanisms of the Antiatherosclerotic Effects of Glucagon‐Like Peptide‐1 Receptor Agonists. Cardiovascular Therapeutics. https://doi.org/10.1155/cdr/8388511

Vancouver

Zawadzki M, Karczewska-Kupczewska M. Direct or Indirect Action? Mechanisms of the Antiatherosclerotic Effects of Glucagon‐Like Peptide‐1 Receptor Agonists. Cardiovascular Therapeutics. 2026. doi:10.1155/cdr/8388511

BibTeX
@article{Zawadzki2026,
  author = {Zawadzki, Michał and Karczewska-Kupczewska, Monika},
  title = {Direct or Indirect Action? Mechanisms of the Antiatherosclerotic Effects of Glucagon‐Like Peptide‐1 Receptor Agonists},
  journal = {Cardiovascular Therapeutics},
  year = {2026},
  doi = {10.1155/cdr/8388511}
}
Kostenlos starten →